187 related articles for article (PubMed ID: 35058503)
1. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.
Duan L; Perez RE; Calhoun S; Maki CG
Sci Rep; 2022 Jan; 12(1):1049. PubMed ID: 35058503
[TBL] [Abstract][Full Text] [Related]
2. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.
Duan L; Tadi MJ; Maki CG
Sci Rep; 2023 Sep; 13(1):16271. PubMed ID: 37759078
[TBL] [Abstract][Full Text] [Related]
3. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
[TBL] [Abstract][Full Text] [Related]
4. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation.
Uxa S; Bernhart SH; Mages CFS; Fischer M; Kohler R; Hoffmann S; Stadler PF; Engeland K; Müller GA
Nucleic Acids Res; 2019 Sep; 47(17):9087-9103. PubMed ID: 31400114
[TBL] [Abstract][Full Text] [Related]
5. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle regulation: p53-p21-RB signaling.
Engeland K
Cell Death Differ; 2022 May; 29(5):946-960. PubMed ID: 35361964
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM.
Engeland K
Cell Death Differ; 2018 Jan; 25(1):114-132. PubMed ID: 29125603
[TBL] [Abstract][Full Text] [Related]
8. RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
Pentimalli F; Forte IM; Esposito L; Indovina P; Iannuzzi CA; Alfano L; Costa C; Barone D; Rocco G; Giordano A
Oncogene; 2018 Jul; 37(27):3657-3671. PubMed ID: 29606701
[TBL] [Abstract][Full Text] [Related]
9. RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation.
Schade AE; Fischer M; DeCaprio JA
Nucleic Acids Res; 2019 Dec; 47(21):11197-11208. PubMed ID: 31667499
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
11. Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.
Woo JK; Kang JH; Shin D; Park SH; Kang K; Nho CW; Seong JK; Lee SJ; Oh SH
Mol Cancer Ther; 2015 Jul; 14(7):1693-704. PubMed ID: 25882311
[TBL] [Abstract][Full Text] [Related]
12. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
[TBL] [Abstract][Full Text] [Related]
13. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence.
Litovchick L; Sadasivam S; Florens L; Zhu X; Swanson SK; Velmurugan S; Chen R; Washburn MP; Liu XS; DeCaprio JA
Mol Cell; 2007 May; 26(4):539-51. PubMed ID: 17531812
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
15. Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2.
Enrico TP; Stallaert W; Wick ET; Ngoi P; Wang X; Rubin SM; Brown NG; Purvis JE; Emanuele MJ
Elife; 2021 Dec; 10():. PubMed ID: 34851822
[TBL] [Abstract][Full Text] [Related]
16. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.
Duan L; Perez RE; Calhoun S; Maki CG
Sci Rep; 2022 Mar; 12(1):4525. PubMed ID: 35296774
[No Abstract] [Full Text] [Related]
17. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
18. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins.
Böhlig L; Friedrich M; Engeland K
Nucleic Acids Res; 2011 Jan; 39(2):440-53. PubMed ID: 20833636
[TBL] [Abstract][Full Text] [Related]
19. Inorganic arsenic exposure induces E2F-dependent G0/G1 arrest via an increase in retinoblastoma family protein p130 in B-cell lymphoma A20 cells.
Okamura K; Miki D; Nohara K
Genes Cells; 2013 Oct; 18(10):839-49. PubMed ID: 23890198
[TBL] [Abstract][Full Text] [Related]
20. Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
Al-Khafaji AS; Davies MP; Risk JM; Marcus MW; Koffa M; Gosney JR; Shaw RJ; Field JK; Liloglou T
Br J Cancer; 2017 Feb; 116(5):592-599. PubMed ID: 28095398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
